Drug Trial Radar · NCT01703559
The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Sep 9, 2011
Primary completion
Apr 16, 2012
Study completion Apr 30, 2012
Sponsor
- Lead sponsor
- Opus Genetics, IncIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objectives of this study are: * To evaluate the efficacy of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) in the treatment of night vision complaints, including reduced contrast sensitivity * To evaluate the ocular and systemic safety of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) compared to its vehicle, a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
Conditions
- Night Vision Complaints
- Decrease in Night Vision
- Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1.0%Drug
Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
Phentolamine Mesylate Ophthalmic Solution 0.5%Drug
Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)Other
Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS FrequenciesTime frame: Postdose Day 1, 4, 8, 15, and Day 15 (LOCF=Last Observation Carried Forward)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Phoenix, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.